edaravone


( Last Updated : August 11, 2022)
Generic Name:
edaravone
Project Status:
Active
Therapeutic Area:
Amyotrophic lateral sclerosis
Manufacturer:
Mitsubishi Tanabe Pharma Canada, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0727-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of amyotrophic lateral sclerosis (ALS)
Submission Type:
Initial
Fee Schedule:
Schedule C
Tumour Type:
N/A
Indications:
For the treatment of amyotrophic lateral sclerosis (ALS).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open09-Feb-22
Call for patient/clinician input closed01-Apr-22
Clarification:

- Patient input submission received from The ALS Society of Canada

Submission received10-Mar-22
Submission accepted24-Mar-22
Review initiated25-Mar-22
Draft CADTH review report(s) provided to sponsor for comment09-Jun-22
Deadline for sponsors comments20-Jun-22
CADTH review report(s) and responses to comments provided to sponsor15-Jul-22
Expert committee meeting (initial)27-Jul-22
Draft recommendation issued to sponsor
Clarification:

- CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements.

Draft recommendation posted for stakeholder feedback
End of feedback period